Animal models for neonatal diseases in humans

Vaccine

Volumn 31, Issue 21, 2013, Pages 2489-2499

  Levast, Benoît ^a   Schulz, Sandra ^a   Hurk, Sylvia van Drunen Littel van den ^a,b   Gerdts, Volker ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Animal models; Infant immunity; Review

Indexed keywords

BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GANCICLOVIR; GLYCOPROTEIN D; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MIFAMURTIDE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN STX2B TIR STX1B ZOT; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; BORDETELLA PERTUSSIS; BRONCHIOLITIS; CATTLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLOSTRIDIUM DIFFICILE; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; DISEASE MODEL; DRUG EFFICACY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GRANULOCYTE; GUINEA PIG; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HERPES SIMPLEX; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEWBORN DISEASE; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PERTUSSIS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; PROTECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; ROTAVIRUS INFECTION; SALMONELLA ENTERICA; SEROCONVERSION; SHEEP; STREPTOCOCCUS PNEUMONIA; SWINE; TETANUS; TREATMENT RESPONSE; TUBERCULOSIS; TYPHOID FEVER; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CHILD; DISEASE MODELS, ANIMAL; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; VACCINES;

EID: 84877817491     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.089     Document Type: Review

References (126)

1. PrabhuDas M., Adkins B., Gans H., King C., Levy O., Ramilo O., et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 2011 Mar, 12(3):189-194.
2. Gerdts V., Littel-van den Hurk S.D., Griebel P.J., Babiuk L.A. Use of animal models in the development of human vaccines. Future Microbiol 2007, 2(December (6)):667-675.
3. Gerdts V., Uwiera R.R., Mutwiri G.K., Wilson D.J., Bowersock T., Kidane A., et al. Multiple intestinal 'loops' provide an in vivo model to analyse multiple mucosal immune responses. J Immunol Methods 2001, 256(October (1-2)):19-33.
4. Elahi S., Holmstrom J., Gerdts V. The benefits of using diverse animal models for studying pertussis. Trends Microbiol 2007, 15(October (10)):462-468.
5. Bishop S.C., Lunney J.K., Pinard-van der Laan M.H., Gay C.G. Report from the second international symposium on animal genomics for animal health: critical needs, challenges and potential solutions. BMC Proc 2011, 5(Suppl. 4):S1.
6. Yorita K.L., Holman R.C., Sejvar J.J., Steiner C.A., Schonberger L.B. Infectious disease hospitalizations among infants in the United States. Pediatrics 2008, 121(February (2)):244-252.
7. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(May (9725)):1545-1555.
8. McIntyre P., Wood N. Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis 2009, 22(June (3)):215-223.
9. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342(January (4)):225-231.
10. Wood N., Siegrist C.A. Neonatal immunization: where do we stand?. Curr Opin Infect Dis 2011, 24(June (3)):190-195.
11. Demirjian A., Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol 2009, 39(January (1)):36-46.
12. Thomas L.H., Stott E.J., Jones P.W., Jebbett N.J., Collins A.P. The possible role of respiratory syncytial virus and Pasteurella spp in calf respiratory disease. Vet Rec 1980, 107(September (13)):304-307.
13. Kim H.W., Arrobio J.O., Brandt C.D., Jeffries B.C., Pyles G., Reid J.L., et al. Epidemiology of respiratory syncytial virus infection in Washington, D. C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 1973, 98(September (3)):216-225.
14. Cormier S.A., You D., Honnegowda S. The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert Rev Anti Infect Ther 2010, 8(December (12)):1371-1380.
15. Prince G., Jenson A., Horswood J., Canargo E., Chanock R. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978, 93(3):771-791.
16. De Swart R.L., Kuiken T., Timmerman H.H., van Amerongen G., Van Den Hoogen B.G., Vos H.W., et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 2002, 76(November (22)):11561-11569.
17. Vaughan K., Rhodes G.H., Gershwin L.J. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 2005, 23(April (22)):2928-2942.
18. Olivier A., Gallup J., de Macedo M.M., Varga S.M., Ackermann M. Human respiratory syncytial virus A2 strain replicates and induces innate immune responses by respiratory epithelia of neonatal lambs. Int J Exp pathol 2009, 90(August (4)):431-438.
19. Sow F.B., Gallup J.M., Olivier A., Krishnan S., Patera A.C., Suzich J., et al. Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs. Am J Physiol Lung Cell Mol Physiol 2011, 300(January (1)):L12-L24.
20. LeBlanc P.H., Baker J.C., Gray P.R., Robinson N.E., Derksen F.J. Effects of bovine respiratory syncytial virus on airway function in neonatal calves. Am J Vet Res 1991, 52(September (9)):1401-1406.
21. Kawashima K., Meyerholz D.K., Gallup J.M., Grubor B., Lazic T., Lehmkuhl H.D., et al. Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus. Vir immunol 2006, 19(2):316-323. Summer.
22. Meyerholz D.K., Grubor B., Fach S.J., Sacco R.E., Lehmkuhl H.D., Gallup J.M., et al. Reduced clearance of respiratory syncytial virus infection in a preterm lamb model. Microbes Infect/Institut Pasteur 2004, 6(November (14)):1312-1319.
23. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(April (4)):422-434.
24. Antonis A.F., Schrijver R.S., Daus F., Steverink P.J., Stockhofe N., Hensen E.J., et al. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J Virol 2003, 77(November (22)):12067-12073.
25. Becnel D., You D., Erskin J., Dimina D.M., Cormier S.A. A role for airway remodeling during respiratory syncytial virus infection. Respir Res 2005, 6:122.
26. Culley F.J., Pollott J., Openshaw P.J. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002, 196(November (10)):1381-1386.
27. Dakhama A., Park J.W., Taube C., Joetham A., Balhorn A., Miyahara N., et al. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J Immunol 2005, 175(August (3)):1876-1883.
28. You D., Becnel D., Wang K., Ripple M., Daly M., Cormier S.A. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respir Res 2006, 7:107.
29. Plotnicky H., Siegrist C.A., Aubry J.P., Bonnefoy J.Y., Corvaia N., Nguyen T.N., et al. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Vaccine 2003, 21(June (19-20)):2651-2660.
30. McArthur-Vaughan K., Gershwin L.J. A rhesus monkey model of respiratory syncytial virus infection. J Med Primatol 2002, 31(April (2)):61-73.
31. Stott E.J., Taylor G. Respiratory syncytial virus. Brief review. Arch Virol 1985, 84(1-2):1-52.
32. Ellis J., Gow S., West K., Waldner C., Rhodes C., Mutwiri G., et al. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration. J Am Vet Med Assoc 2007, 230(January (2)):233-243.
33. Hamers C., Juillard V., Fischer L. DNA vaccination against pseudorabies virus and bovine respiratory syncytial virus infections of young animals in the face of maternally derived immunity. J Comp Pathol 2007, 137(July (Suppl.1)):S35-S41.
34. Mapletoft J.W., Oumouna M., Townsend H.G., Gomis S., Babiuk L.A., van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 2006, 353(September (2)):316-323.
35. Vainionpaa R., Hyypia T. Biology of parainfluenza viruses. Clin Microbiol Rev 1994, 7(April (2)):265-275.
36. Sato M., Wright P.F. Current status of vaccines for parainfluenza virus infections. Pediatr Infect Dis J 2008, 27(October (Suppl. 10)):S123-S125.
37. Bot A., Bot S., Bona C. Enhanced protection against influenza virus of mice immunized as newborns with a mixture of plasmids expressing hemagglutinin and nucleoprotein. Vaccine 1998, 16(October (17)):1675-1682.
38. Bot A., Bot S., Garcia-Sastre A., Bona C. Protective cellular immunity against influenza virus induced by plasmid inoculation of newborn mice. Dev Immunol 1998, 5(3):197-210.
39. Hwang S.D., Shin J.S., Ku K.B., Kim H.S., Cho S.W., Seo S.H. Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination. Vaccine 2010, 28(April (17)):2957-2964.
40. Lefevre E.A., Carr B.V., Inman C.F., Prentice H., Brown I.H., Brookes S.M., et al. Immune Responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes. PLoS ONE 2012, 7(3):e32400.
41. Vergara-Alert Jl, Argilaguet J.M., Busquets Nr, Ballester M., Martãn-Valls G.E., Rivas R., et al. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model. PLoS ONE 2012, 7(7):e40524.
42. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
43. Ciarlet M., Conner M.E. Evaluation of rotavirus vaccines in small animal models. Method Mol Med 2000, 34:147-187.
44. Conner M.E., Estes M.K., Graham D.Y. Rabbit model of rotavirus infection. J Virol 1988, 62(May (5)):1625-1633.
45. Conner M.E., Gilger M.A., Estes M.K., Graham D.Y. Serologic and mucosal immune response to rotavirus infection in the rabbit model. J Virol 1991, 65(May (5)):2562-2571.
46. Ciarlet M., Crawford S.E., Barone C., Bertolotti-Ciarlet A., Ramig R.F., Estes M.K., et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 1998, 72(November (11)):9233-9246.
47. Ward R.L., McNeal M.M., Sheridan J.F. Development of an adult mouse model for studies on protection against rotavirus. J Virol 1990, 64(October (10)):5070-5075.
48. O'Neal C.M., Crawford S.E., Estes M.K., Conner M.E. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 1997, 71(November (11)):8707-8717.
49. McNeal M.M., Rae M.N., Conner M.E., Ward R.L. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology 1998, 243(March (1)):158-166.
50. Jiang B., Estes M.K., Barone C., Barniak V., O'Neal C.M., Ottaiano A., et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 1999, 17(February (7-8)):1005-1013.
51. Warfield K.L., Blutt S.E., Crawford S.E., Kang G., Conner M.E. Rotavirus infection enhances lipopolysaccharide-induced intussusception in a mouse model. J Virol 2006, 80(December (24)):12377-12386.
52. González A.M., Azevedo M.S.P., Jung K., Vlasova A., Zhang W., Saif L.J. Innate immune responses to human rotavirus in the neonatal gnotobiotic piglet disease model. Immunology 2010, 131(2):242-256.
53. Hoshino Y., Saif L.J., Kang S.-Y., Sereno M.M., Chen W.-K., Kapikian A.Z. Identification of group A rotavirus genes associated with virulence of a porcine rotavirus and host range restriction of a human rotavirus in the gnotobiotic piglet model. Virology 1995, 209(1):274-280.
54. Saif L.J., Ward L.A., Yuan L., Rosen B.I., To T.L. The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses. Arch Virol Suppl 1996, 12:153-161.
55. Yuan L., Saif L.J. Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model. Vet Immunol Immunopathol 2002, 87(September (3-4)):147-160.
56. Ward L.A., Rosen B.I., Yuan L., Saif L.J. Pathogenesis of an attenuated and a virulent strain of group A human rotavirus in neonatal gnotobiotic pigs. J Gen Virol 1996, 77(July (Pt 7)):1431-1441.
57. Wen K., Azevedo M.S., Gonzalez A., Zhang W., Saif L.J., Li G., et al. Toll-like receptor and innate cytokine responses induced by lactobacilli colonization and human rotavirus infection in gnotobiotic pigs. Vet Immunol Immunopathol 2009, 127(February (3-4)):304-315.
58. Wen K., Bui T., Li G., Liu F., Li Y., Kocher J., et al. Characterization of immune modulating functions of γδ T cell subsets in a gnotobiotic pig model of human rotavirus infection. Comp Immunol Microbiol Infect Dis 2012, 0.
59. Wen K., Li G., Bui T., Liu F., Li Y., Kocher J., et al. High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs. Vaccine 2011, 30(6):1198-1207.
60. Wang Y., Azevedo M., Saif L.J., Gentsch J.R., Glass R.I., Jiang B. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine 2012, 28(33):5432-5436.
61. Fazio V.M., Ria F., Franco E., Rosati P., Cannelli G., Signori E., et al. Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization. Gene Ther 2004, 11(6):544-551.
62. Gerdts V., Tsang C., Griebel P.J., Babiuk L.A. DNA vaccination in utero: a new approach to induce protective immunity in the newborn. Vaccine 2004, 22:1717-1727. 13-14.
63. Clements D.E., Coller B-AG, Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28(15):2705-2715.
64. Onlamoon N., Noisakran S., Hsiao H.-M., Duncan A., Villinger F., Ansari A.A., et al. Dengue virus induced hemorrhage in a nonhuman primate model. Blood 2010, March (115)(9):1823-1834.
65. Ramanathan M.P., Kuo Y.-C., Selling B.H., Li Q., Sardesai N.Y., Kim J.J., et al. Development of a novel DNA SynCon™ tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine 2009, 27(46):6444-6453.
66. Zompi S., Santich B.H., Beatty P.R., Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 2012, 188(January (1)):404-416.
67. Yauch L.E., Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res 2008, 80(2):87-93.
68. Sato Y., Izumiya K., Sato H., Cowell J.L., Manclark C.R. Aerosol infection of mice with Bordetella pertussis. Infec Immun 1980, 29(July (1)):261-266.
69. Hale C., Humphreys I.R., Hussell T., Bowe F., Clare S., Pickard D., et al. Mucosal immunisation of murine neonates using whole cell and acellular Pertussis vaccines. Vaccine 2004, 22(September (27-28)):3595-3602.
70. Nascimento I.P., Dias W.O., Quintilio W., Christ A.P., Moraes J.F., Vancetto M.D., et al. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge. Microbes Infect/Institut Pasteur 2008, 10(February (2)):198-202.
71. Gracia A., Polewicz M., Halperin S.A., Hancock R.E., Potter A.A., Babiuk L.A., et al. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine 2011, 29(February (8)):1595-1604.
72. Garlapati S., Eng N.F., Kiros T.G., Kindrachuk J., Mutwiri G.K., Hancock R.E., et al. Immunization with PCEP microparticles containing pertussis toxoid CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 2011, 29(September (38)):6540-6548.
73. Elahi S., Brownlie R., Korzeniowski J., Buchanan R., O'Connor B., Peppler M.S., et al. Infection of newborn piglets with Bordetella pertussis: a new model for pertussis. Infect Immun 2005, 73(June (6)):3636-3645.
74. Elahi S., Buchanan R.M., Babiuk L.A., Gerdts V. Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun 2006, 74(May (5)):2619-2627.
75. Polewicz M., Gracia A., Buchanan R., Strom S., Halperin S.A., Potter A.A., et al. Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets. Vaccine 2011, (August).
76. Warfel J.M., Beren J., Kelly V.K., Lee G., Merkel T.J. A non-human primate model of pertussis. Infect Immun 2012, 17(January):2012.
77. Tzipori S., Gunzer F., Donnenberg M.S., de Montigny L., Kaper J.B., Donohue-Rolfe A. The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect Immun 1995, 63(September (9)):3621-3627.
78. Cantey J.R., O'Hanley P.D., Blake R.K. A rabbit model of diarrhea due to invasive Escherichia coli. J Infect Dis 1977, 136(November (5)):640-648.
79. Agin T.S., Cantey J.R., Boedeker E.C., Wolf M.K. Characterization of the eaeA gene from rabbit enteropathogenic Escherichia coli strain RDEC-1 and comparison to other eaeA genes from bacteria that cause attaching-effacing lesions. FEMS Microbiol Lett 1996, 144(Novemeber (2-3)):249-258.
80. Luperchio S.A., Schauer D.B. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes infect/Institut Pasteur 2001, 3(April (4)):333-340.
81. Mohawk K.L., O'Brien A.D. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. J Biomed Biotechnol 2011, 258185.
82. Wadolkowski E.A., Burris J.A., O'Brien A.D. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 1990, 58(August (8)):2438-2445.
83. Lindgren S.W., Melton A.R., O'Brien A.D. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect Immun 1993, 61(September (9)):3832-3842.
84. Isogai E., Isogai H., Kimura K., Hayashi S., Kubota T., Fujii N., et al. Role of tumor necrosis factor alpha in gnotobiotic mice infected with an Escherichia coli O157:H7 strain. Infect Immun 1998, 66(January (1)):197-202.
85. Asahara T., Shimizu K., Nomoto K., Hamabata T., Ozawa A., Takeda Y. Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun 2004, 72(April (4)):2240-2247.
86. Karpman D., Connell H., Svensson M., Scheutz F., Alm P., Svanborg C. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J infect Dis 1997, 175(March (3)):611-620.
87. Mohawk K.L., Melton-Celsa A.R., Zangari T., Carroll E.E., O'Brien A.D. Pathogenesis of Escherichia coli O157:H7 strain 86-24 following oral infection of BALB/c mice with an intact commensal flora. Microb Pathogenesis 2010, 48(March-April (3-4)):131-142.
88. Horne C., Vallance B.A., Deng W., Finlay B.B. Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines. Expert Rev Vaccines 2002, 1(December (4)):483-493.
89. An H., Fairbrother J.M., Desautels C., Mabrouk T., Dugourd D., Dezfulian H., et al. Presence of the LEE (locus of enterocyte effacement) in pig attaching and effacing Escherichia coli and characterization of eae, espA, espB and espD genes of PEPEC (pig EPEC) strain 1390. Microb Pathog 2000, 28(May (5)):291-300.
90. Potter A.A., Klashinsky S., Li Y., Frey E., Townsend H., Rogan D., et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004, 22(January (3-4)):362-369.
91. Peterson R.E., Klopfenstein T.J., Moxley R.A., Erickson G.E., Hinkley S., Bretschneider G., et al. Effect of a Vaccine Product Containing Type III Secreted Proteins on the Probability of Escherichia coli O157:H7 Fecal Shedding and Mucosal Colonization in Feedlot Cattle. J Food Prot® 2007, 70(11):2568-2577.
92. Yekta MA, Goddeeris BM, Vanrompay D, Cox E. Immunization of sheep with a combination of intiminγ, EspA and EspB decreases Escherichia coli O157:H7 shedding. Veterinary Immunology and Immunopathology;140(1-2):42-46.
93. Zhang X.H., He K.W., Zhao P.D., Ye Q., Luan X.T., Yu Z.Y., et al. Intranasal immunisation with Stx2B-Tir-Stx1B-Zot protein leads to decreased shedding in goats after challenge with Escherichia coli O157:H7. Vet Rec 2012, 170(February (7)):178.
94. Crump J.A., Mintz E.D. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010, 50(January (2)):241-246.
95. Barrow P.A., Page K., Lovell M.A. The virulence for gnotobiotic pigs of live attenuated vaccine strains of Salmonella enterica serovars Typhimurium and Enteritidis. Vaccine 2001, 19(25-26):3432-3436.
96. Haneda T., Okada N., Kikuchi Y., Takagi M., Kurotaki T., Miki T., et al. Evaluation of Salmonella enterica serovar Typhimurium and Choleraesuis slyA mutant strains for use in live attenuated oral vaccines. Comp Immunol Microbiol Infect Dis 2011, 34(5):399-409.
97. Kamath A.T., Rochat A.F., Valenti M.P., Agger E.M., Lingnau K., Andersen P., et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PloS ONE 2008, 3(11):e3683.
98. Endsley J.J., Waters W.R., Palmer M.V., Nonnecke B.J., Thacker T.C., Jacobs W.R., et al. The calf model of immunity for development of a vaccine against tuberculosis. Vet Immunol Immunopathol 2009, 128(March (1-3)):199-204.
99. Buddle B.M., Wedlock D.N., Parlane N.A., Corner L.A., De Lisle G.W., Skinner M.A. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect immun 2003, 71(November (11)):6411-6419.
100. Waters W.R., Palmer M.V., Nonnecke B.J., Thacker T.C., Scherer C.F., Estes D.M., et al. Efficacy and immunogenicity of Mycobacterium bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves. Vaccine 2009, 27(February (8)):1201-1209.
101. Hope J.C., Thom M.L., Villarreal-Ramos B., Vordermeier H.M., Hewinson R.G., Howard C.J. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis. Clin Exp Immunol 2005, 139(January (1)):48-56.
102. Flynn J.L., Capuano S.V., Croix D., Pawar S., Myers A., Zinovik A., et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinburgh, Scotland) 2003, 83(1-3):116-118.
103. Adderson E.E. Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations. Springer Semin Immunopathol 2001, 23(December (4)):387-403.
104. Yang H.H., Madoff L.C., Guttormsen H.K., Liu Y.D., Paoletti L.C. Recombinant group B Streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect immun 2007, 75(July (7)):3455-3461.
105. Santillan D.A., Andracki M.E., Hunter S.K. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. Am J Obstet Gynecol 2008, 198(January (1)). 114 e111-116.
106. Katsurahara T., Hotomi M., Yamauchi K., Billal D.S., Yamanaka N. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA). J Infect Chemother 2008, 14(December (6)):393-398.
107. Sabirov A., Metzger D.W. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 2006, 24(July (27-28)):5584-5592.
108. Olafsdottir T.A., Lingnau K., Nagy E., Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scan J Immunol 2009, 69(March (3)):194-202.
109. Larsen J.W., Harper J.S., London W.T., Baker C.J., Curfman B.L., Kasper D.L., et al. Antibody to type III group B Streptococcus in the rhesus monkey. Am J Obstet Gynecol 1983, 146(August (8)):958-962.
110. Larsen J.W., London W.T., Palmer A.E., Tossell J.W., Bronsteen R.A., Daniels M., et al. Experimental group B streptococcal infection in the rhesus monkey. I. Disease production in the neonate. Am J Obstet Gynecol 1978, 132(November (6)):686-690.
111. Barnoy S., Baqar S., Kaminski R.W., Collins T., Nemelka K., Hale T.L., et al. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Vaccine 2011, 29(37):6371-6378.
112. Barman S., Saha D.R., Ramamurthy T., Koley H. Development of a new guinea-pig model of shigellosis. FEMS Immunol Med Microbiol 2011, 62(3):304-314.
113. Jeong K-i, Zhang Q., Nunnari J., Tzipori S. A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1. J Infect Dis 2010, 201(March (6)):903-911.
114. Steele J., Feng H., Parry N., Tzipori S. Piglet models of acute or chronic clostridium difficile illness. J Infect Dis 2010, 201(February (3)):428-434.
115. Abd Alla M.D., White G.L., Rogers T.B., Cary M.E., Carey D.W., Ravdin J.I. Adherence-inhibitory intestinal immunoglobulin A antibody response in baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine. Infect Immun 2007, 75(August (8)):3812-3822.
116. Guang-Zhi H. Entamoeba histolytica: cloning, expression and evaluation of the efficacy of a recombinant amebiasis cysteine proteinase gene (ACP1) antigen in minipig. Exp Parasitol 2012, 130(2):126-129.
117. Girard-Misguich F., Cognie J., Delgado-Ortega M., Berthon P., Rossignol C., Larcher T., et al. Towards the establishment of a porcine model to study human amebiasis. PLoS ONE 2011, 6(12):e28795.
118. González-Vázquez M.C., Carabarin-Lima A., Baylón-Pacheco L., Talamás-Rohana P., Rosales-Encina J.L. Obtaining of three recombinant antigens of Entamoeba histolytica and evaluation of their immunogenic ability without adjuvant in a hamster model of immunoprotection. Acta Trop 2012, 0.
119. Petri W.A., Chaudhry O., Haque R., Houpt E. Adherence-blocking vaccine for amebiasis. Arch Med Res 2006, 37(2):287-290.
120. Tachibana M, Sato C, Otsuki H, Sattabongkot J, Kaneko O, Torii M, et al. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate. Vaccine;30(10):1807-1812.
121. Daubenberger C.A., Salomon M., Vecino W., Hübner B., Troll H., Rodriques R., et al. Functional and structural similarity of V γ 9V δ 2 T cells in humans and aotus monkeys, a primate infection model for Plasmodium falciparum malaria. J Immunol 2001, 167(December (11)):6421-6430.
122. Khosroshahi K., Ghaffarifar F., Sharifi Z., D'Souza S., Dalimi A., Hassan Z., et al. Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii. Parasitol Res 2012, 1-9.
123. Cui X., Lei T., Yang D., Hao P., Li B., Liu Q. Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis. Vaccine 2012, 0.
124. Dubey J.P., Ferreira L.R., Martins J., McLeod R. Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality. Parasitology 2012, 139(01):1-13.
125. Elisabeth A.I. Toxoplasmosis: comparative species susceptibility and host immune response. Comp Immunol Microbiol Infect Dis 1997, 20(2):131-138.
126. Esteban-Redondo I., Maley S.W., Thomson K., Nicoll S., Wright S., Buxton D., et al. Detection of T. gondii in tissues of sheep and cattle following oral infection. Vet Parasitol 1999, 86(3):155-171.